NCT03736512已完成不适用
Prospective Registry of Outcomes With the GreenLight™ Laser System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- The GreenLight XPS system provides durable relief of BPH symptoms in subjects.
研究概览
简要总结
The duration of the study is expected to take approximately 3 years, which includes a recruitment period of approximately 12-months and 2 years (24-months) to complete procedure and follow-up visits.
详细描述
The study follow-up duration from the primary study procedure is 5 years.
- Baseline
- Study Procedure
- 4-week
- 6-month
- 12-month
- 24-month (End of Study) The study will be considered complete after all subjects have completed the 24-month follow-up visit.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject has provided informed consent and agrees to attend all study visits
- •Subject has a diagnosis of lower urinary tract symptoms due to benign prostatic enlargement causing bladder outlet obstruction
- •Subject is able to complete self-administered questionnaires
- •Clinical investigator has documented in the subject's medical record that in his/her judgment the subject is a surgical candidate for the PVP procedure
- •Subject is ≥ 40 years of age
- •Subject has an IPSS score greater than or equal to 12 measured at the baseline visit
- •Subject has medical record documentation of a maximum urinary flow rate (Qmax) less than or equal to 15ml/s and sample is greater than or equal to 150ml (If uroflow testing documentation is available within 90 days prior to the informed consent date, and the sample is greater than or equal to 150ml, and the Qmax is less than or equal to 15ml/s it may be used for the inclusion/exclusion criteria)
- •Subject has medical record documentation of a prostate volume of greater than or equal to 30 grams by transrectal ultrasound (TRUS))
排除标准
- •Subject has a life expectancy of less than 2 years
- •Subject is classified as American Society of Anesthesiologists (ASA) V
- •Subject is currently enrolled in, or plans to enroll in, any concurrent drug or device study unless preapproved by the sponsor
- •Subject has an active infection that would preclude operation within 14 days of the study procedure (e.g., urinary tract infection or prostatitis)
- •Subject has a diagnosis of, or has received treatment for, chronic prostatitis or chronic pelvic pain syndrome (e.g., non-bacterial chronic prostatitis)
- •Subject has a neurogenic bladder or other neurological disorder that would impact bladder function (e.g., multiple sclerosis, Parkinson's disease, spinal cord injuries)
- •Subject has a diagnosis of polyneuropathy (e.g., diabetic)
- •Subject has diagnosis of stress urinary incontinence that requires treatment or daily pad/device use
- •Subject has a diagnosis of prostate cancer or suspected prostate cancer based on PSA results and meeting the following:
- •PSA level of 4 - 10 with an abnormal DRE (if biopsy collected must be positive); PSA level greater than 10 with a positive biopsy
- •Subject has a history of CIS, TaGIII or any T1 stage bladder cancer
- •Subject has damage to external urinary sphincter
- •Subject has had an acute myocardial infarction, open heart surgery or cardiac arrest less than 180 days prior to the date of informed consent
- •Subject is immunocompromised (e.g., organ transplant, leukemia)
- •Subject currently or has a history of upper urinary tract stones
- •Subject currently diagnosed with OAB and treated with medication If the subject does not carry a diagnosis but is suspected to have OAB, the investigator must use his/her discretion
结局指标
主要结局
The GreenLight XPS system provides durable relief of BPH symptoms in subjects.
时间窗: 6-month follow up
Changes of IPSS Scores in subjects treated with the GreenLight XPS Laser System at 6 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Atorvastatin Three Year Pediatric StudyFamilial HypercholesterolemiaNCT00827606Pfizer's Upjohn has merged with Mylan to form Viatris Inc.272
已完成
不适用
StimRouter Registry Clinical ProtocolChronic PainNervous System DiseasesPeripheral Nervous System DiseasesPeripheral Nervous System ProblemPeripheral Nerve InjuriesPeripheral NervousPeripheral NeuropathyNCT03913689Bioness Inc62
已完成
3 期
A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.Virus DiseasesRabiesNCT02545517GlaxoSmithKline459
已完成
不适用
An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year PeriodMultiple SclerosisNCT01112657Merck KGaA, Darmstadt, Germany154
终止
不适用
The Chimerix CMX001 RegistryOutcomesSurvival RatesNCT02167685Chimerix550